Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2041 AL 2055

A review ofimaging genetics in Alzheimer's disease

Xin Y, Sheng J, Miao M, Wang L, Yang Z, Huang H.

J Clin Neurosci. 2022 Jun;100:155-163. doi: 10.1016/j.jocn.2022.04.017. Epub 2022 Apr 26.

PET Imaging in Preclinical Anti-Aβ Drug Development

Syvänen S, Meier SR, Roshanbin S, Xiong M, Faresjö R, Gustavsson T, Bonvicini G, Schlein E, Aguilar X, Julku U, Eriksson J, Sehlin D.

Pharm Res. 2022 Jul;39(7):1481-1496. doi: 10.1007/s11095-022-03277-z. Epub 2022 May 2.

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy

Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, Castrillo-Viguera C, Rubino I, Vijverberg E.

J Prev Alzheimers Dis. 2022;9(2):211-220. doi: 10.14283/jpad.2022.21.

A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease

Schneider LS, Laudon M, Nir T, Caceres J, Ianniciello G, Capulli M, Zisapel N.

J Prev Alzheimers Dis. 2022;9(2):247-254. doi: 10.14283/jpad.2021.61.

Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer's Disease

Pradhan LK, Sahoo PK, Chauhan S, Das SK.

J Mol Neurosci. 2022 Jun;72(6):1143-1165. doi: 10.1007/s12031-022-02009-7. Epub 2022 May 12.

Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease

Takata K, Kimura H, Yanagisawa D, Harada K, Nishimura K, Kitamura Y, Shimohama S, Tooyama I.

Molecules. 2022 Apr 27;27(9):2780. doi: 10.3390/molecules27092780.

Alzheimer disease neuropathology in a patient previously treated with aducanumab

Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C, Castrillo-Viguera C, Sandrock A, Budd Haeberlein S, van Dyck CH, Huttner A.

Acta Neuropathol. 2022 Jul;144(1):143-153. doi: 10.1007/s00401-022-02433-4. Epub 2022 May 17.

The Current Landscape of Prevention Trials in Dementia

Lee J, Howard RS, Schneider LS.

Neurotherapeutics. 2022 Jan;19(1):228-247. doi: 10.1007/s13311-022-01236-5. Epub 2022 May 19.

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD.

J Nucl Med. 2022 Jun;63(Suppl 1):13S-19S. doi: 10.2967/jnumed.121.263195.

Application of curcumin nanoformulations in Alzheimer's disease: prevention, diagnosis and treatment

Lv H, Wang Y, Yang X, Ling G, Zhang P.

Nutr Neurosci. 2023 Aug;26(8):727-742. doi: 10.1080/1028415X.2022.2084550. Epub 2022 Jun 11.

Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research

Yang H, Zeng F, Luo Y, Zheng C, Ran C, Yang J.

Molecules. 2022 Jun 17;27(12):3879. doi: 10.3390/molecules27123879.

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease

Cohen S, Cummings J, Knox S, Potashman M, Harrison J.

J Prev Alzheimers Dis. 2022;9(3):507-522. doi: 10.14283/jpad.2022.41.

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study

Cuberas-Borrós G, Roca I, Castell-Conesa J, Núñez L, Boada M, López OL, Grifols C, Barceló M, Pareto D, Páez A.

Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4589-4600. doi: 10.1007/s00259-022-05915-5. Epub 2022 Jul 22.

Intermittent theta burst stimulation for the treatment of autonomic dysfunction and depressive symptoms in dementia with Lewy bodies

Huang CC, Liang CS, Chu HT, Chang HA, Yeh TC.

Asian J Psychiatr. 2022 Sep;75:103212. doi: 10.1016/j.ajp.2022.103212. Epub 2022 Jul 16.

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Hoang K, Watt H, Golemme M, Perry RJ, Ritchie C, Wilson D, Pickett J, Fox C, Howard R, Malhotra PA.

Trials. 2022 Aug 1;23(1):623. doi: 10.1186/s13063-022-06190-3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias